These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...

All opinions and views are of the advertiser and do not reflect the same of WFTS. Advertiser: Bayer As we usher in 2025, it’s the perfect time to prioritize health and wellness. Registered ...

(Bloomberg) -- Bayer AG plans to push pause on some of ... said in an interview on Monday on the sidelines of the JPMorgan Healthcare Conference in San Francisco. That marks a reversal of comments ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) announced Thursday that elinzanetant, its experimental therapy for hot flashes, reached the ...

However, Bayer's top-selling pharma product Xarelto (rivaroxaban), an anticoagulant, continued to succumb to generic competition with a near-11% fall to €904 million. The solid quarter is ...